12:00 AM
May 10, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Status

RFS 2000: Expanded Phase III trial

SuperGen Inc. (SUPG), San Ramon, Calif.
Product: RFS 2000
Business: Cancer
Therapeutic category: Cell proliferation
Target: Topoisomerase I...

Read the full 82 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >